Validation of high-risk HPV tests for primary cervical screening.
about
Comparing the Cervista HPV HR test and Hybrid Capture 2 assay in a Dutch screening population: improved specificity of the Cervista HPV HR test by changing the cut-off.Protecting the underscreened women in developed countries: the value of HPV testPrediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, SpainPrevalence of low-risk HPV types and genital warts in women born 1988/89 or 1983/84 -results of WOLVES, a population-based epidemiological study in Wolfsburg, GermanyA study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening resultsClinical validation of the cobas 4800 HPV test for cervical screening purposes.Prevalence of human papillomavirus infection in women in Benin, West Africa.HPV prevalence and type distribution in women with or without cervical lesions in the Northeast region of RomaniaCytology and human papillomavirus testing 6 to 12 months after ASCUS or LSIL cytology in organized screening to predict high-grade cervical neoplasia between screening roundsHPV Prevalence in the Dutch cervical cancer screening population (DuSC study): HPV testing using automated HC2, cobas and Aptima workflowsLaboratory and clinical aspects of human papillomavirus testingHPV testing in first-void urine provides sensitivity for CIN2+ detection comparable with a smear taken by a clinician or a brush-based self-sample: cross-sectional data from a triage population.Human Papillomavirus Laboratory Testing: the Changing ParadigmClinical validation of hrHPV testing on vaginal and urine self-samples in primary cervical screening (cross-sectional results from the Papillomavirus Dumfries and Galloway-PaVDaG study).Clinical validation of the Abbott RealTime High Risk HPV assay according to the guidelines for human papillomavirus DNA test requirements for cervical screening.The Aptima HPV assay fulfills the cross-sectional clinical and reproducibility criteria of international guidelines for human papillomavirus test requirements for cervical screeningClinical validation of the HPV-risk assay, a novel real-time PCR assay for detection of high-risk human papillomavirus DNA by targeting the E7 region.Interlaboratory reproducibility and proficiency testing within the human papillomavirus cervical cancer screening program in Catalonia, Spain.Commercially available assays for multiplex detection of alpha human papillomaviruses.Assessment of clinical and analytical performance characteristics of an HPV genotyping test.Understanding HPV tests and their appropriate applications.The current position and the future perspectives of cervical cancer screening.HPV load and anal cytological abnormalities.Hybrid capture II and PapilloCheck® tests for detection of anal high-risk human papillomavirus.Evaluation of commercial HPV assays in the context of post-treatment follow-up: Scottish Test of Cure Study (STOCS-H).Viral and cellular biomarkers in the diagnosis of cervical intraepithelial neoplasia and cancer.Comparison of the Cepheid Xpert HPV test and the HC2 High-Risk HPV DNA Test for detection of high-risk HPV infection in cervical smear samples in SurePath preservative fluid.Oropharynx HPV status and its relation to HIV infection.Validation of intra- and inter-laboratory reproducibility of the Xpert HPV assay according to the international guidelines for cervical cancer screening
P2860
Q33933176-5A0CA5E5-7D63-4D45-BEB2-3685CC688C96Q34062696-C9304711-AE82-4DE8-A3A4-FCE910A88D3AQ34141990-D2FFB02A-9B84-47C4-8121-D4DB3781B971Q34520216-A8951302-D171-43C6-A74F-232D88E2C32EQ34916671-F7666015-C501-4BC7-9F51-2CA0283A94BCQ35530540-0C463776-4BED-4F39-808B-5B4D9A8A099BQ35596164-22BA8AAC-70F4-4582-9DED-F6A404F5A3D1Q35669798-CA9591A2-3C2F-4D52-857B-405AB1EF45D5Q36023019-560BA175-E53C-414B-92FC-80BE96269D88Q36205998-D5F9A27E-124C-4295-B414-B55818B2D9E2Q36311573-66638BF4-9E5D-4D8D-BA52-3A6C2876E9E5Q36341195-A0686055-8DF4-4429-A1B7-E9A1F3A8EF45Q36675236-EEFB5B57-63C3-4F04-A20C-AD34D7B4730FQ36861256-6680ED69-449F-4F86-9E74-4AE3225E53D9Q36971059-2D849840-3223-4768-9577-EB8438D395CAQ37470374-AD9999EA-AED1-46AA-8574-EDA9FF8198BFQ37643509-4213B22B-13C9-425B-8B02-B867DFED531CQ37713769-F937752C-6C92-460A-9242-C675591CBDF5Q37800921-6699A7D3-7002-4E2B-9AEA-C5E39E9EA698Q37862658-EF00436E-7F32-414D-8F16-EC773FEE432EQ38133612-3E6FFC53-88E2-41AA-868D-FD2EEE37F71BQ38168923-35D97273-FC6F-4602-A1DB-E01784383589Q41013102-020F6DFD-1F6B-473C-9F4E-E62E5D8CFE7EQ42216653-93E1F409-8DEB-43A5-BCF4-2059B6C33EEBQ42242703-8BDA56E7-7ED1-4B6A-B806-2E2115D241FCQ42245758-3FCE06AA-D543-4DBD-A95B-65D9574C3070Q53176728-C9A91122-3DDF-4B33-A1FB-1A459D8395D6Q55038584-5ED3D04F-B65D-4CB3-AB13-B9BABE63C408Q58107919-0BB45F62-9F0F-4F66-990C-DD7055AD4A68
P2860
Validation of high-risk HPV tests for primary cervical screening.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Validation of high-risk HPV tests for primary cervical screening.
@en
Validation of high-risk HPV tests for primary cervical screening.
@nl
type
label
Validation of high-risk HPV tests for primary cervical screening.
@en
Validation of high-risk HPV tests for primary cervical screening.
@nl
prefLabel
Validation of high-risk HPV tests for primary cervical screening.
@en
Validation of high-risk HPV tests for primary cervical screening.
@nl
P2093
P1476
Validation of high-risk HPV tests for primary cervical screening.
@en
P2093
A T Hesselink
C J L M Meijer
D A M Heideman
P J F Snijders
P356
10.1016/S1386-6532(09)00540-X
P478
46 Suppl 3
P577
2009-11-01T00:00:00Z